Cormorant Asset Management, LP Cytom X Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$9.5 - $19.16 $2.82 Million - $5.69 Million	-296,712 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$12.69 - $18.61 $3.77 Million - $5.52 Million	296,712 New	296,712 $4.48 Million
Q4 2017 Feb 14, 2018	SELL	$19.0 - $23.09 $1.9 Million - $2.31 Million	-100,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$13.53 - $18.17 $1.35 Million - $1.82 Million	100,000	100,000 $1.82 Million

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.